MedTrace Logo

Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

NCT00706550 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2014-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment (ART). Participants in this study will be assigned by chance to receive vaccination with PV prior to starting ART or after at least 6 months of ART. Antibody levels to components of the PV will be measured at 6 months and 12 months after vaccination. The results will tell us if patients that receive PV after 6 months of ART have better response to the vaccine than those that get vaccinated prior to treatment.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

(PV) 23-valent pneumococcal polysaccharide vaccine

Currently commercially available pneumococcal polysaccharide vaccine

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Maria Rodriguez-Barradas, MD · Michael E. DeBakey VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00706550 on ClinicalTrials.gov